

Astaxanthin from Algae is Superior to Synthetic Astaxanthin and Astaxanthin from *Phaffia* Yeast as Evidenced in Eight Published Studies

IRVINE, CA, USA, January 29, 2019 – [Algae Health Sciences](#), a division of [BGG](#), announced the peer-reviewed publication of a review paper which evaluates head-to-head studies comparing Astaxanthin from three different sources in animals and in-vitro. In each case, Astaxanthin from the algal species *Haematococcus pluvialis* proved significantly more efficacious and biologically active than either Synthetic Astaxanthin or Astaxanthin from the genetically-mutated yeast called *Phaffia*. Six animal studies tested the different forms for a variety of health benefits and found the algal-based form performed significantly better for a variety of health benefits such as increasing lifespan; treating skin cancer; preventing the formation of gastric ulcers; improving resistance to stress; improving exercise endurance; decreasing reactive oxygen species (ROS); and augmenting enzyme levels. Furthermore, two antioxidant studies found that Algal Astaxanthin has 14X to 90X greater antioxidant activity than Synthetic Astaxanthin (Capelli, Talbott, Ding, 2019).

“In addition to these eight studies demonstrating superior efficacy and activity for Algal Astaxanthin, it’s important to understand that there are absolutely no human clinical trials we found demonstrating any health benefit or even safety for the alternative Astaxanthin forms,” said Shawn Talbott, PhD, President of EQQIL (a clinical research organization) who was an author of the review paper. “Until clinical trials are published on Synthetic Astaxanthin and Astaxanthin from *Phaffia* yeast showing efficacy and long-term human safety studies are conducted, our conclusion is that consumers should ensure that they’re supplementing with algal-based Astaxanthin. Algal Astaxanthin has over 100 clinical trials showing efficacy, numerous human safety studies, and twenty years of consumer use in the market.”

“The consistency of the results of these eight different studies is noteworthy in that the algal form of Astaxanthin always came out on top,” added Bob Capelli, lead author of the review paper. “In most of the studies, the differences in results between the three forms were quite striking.”

Reference:

Capelli, B., Talbott, S., Ding, L. (2019). “Astaxanthin sources: Suitability for human health and nutrition.” *Functional Foods in Health and Disease* 2019;9(6):430-445.

Anyone wishing to receive the full paper should contact info@algaehealthsciences.com

About Algae Health Sciences, Inc: Algae Health Sciences, Inc., a subsidiary of BGG, focuses on the production and marketing of efficacious ingredients from natural algae sources. With the second largest capacity to produce Natural Astaxanthin from microalgae, Algae Health Sciences plans to become the world's largest producer by 2022. The company has facilities in USA, Switzerland, Japan and China.

Further Information on Algae Health Sciences: www.algaehealthsciences.com

About BGG: BGG is a global B2B supplier of ingredients sourced from nature that improve consumer wellness. Building on 25 years of innovative leadership, BGG provides consumer product makers with efficacious ingredients of outstanding quality. This is achieved by specialized sourcing, cultivation and production in the best global regions. BGG's extensive portfolio originates from algae, fruits and plants. BGG employs a staff of approximately 450, has 6 production sites, international branches in North America, Japan, China and Switzerland and manages sales in over 100 countries. BGG is ISO9001, ISO22000 and GMP certified.

Further Information on BGG: www.bggworld.com

Press Contacts:

Algae Health Sciences, Inc.

Bob Capelli
Executive Vice President Global Marketing
bob@algaehealthsciences.com

BGG

Christian Artaria
CEO BGG Europe and CMO of BGG Group
christian.artaria@bggworld.com